EGFR and neoplasm: At present, the primary tumor location is clearly stated in domestic and international clinical practice guidelines as a surrogate biomarker for the selection of anti-EGFR antibody drugs, but in the future, it is expected to be replaced by the evaluation of the methylation status of the entire genome.